q 2006 by Taylor & Francis Group, LLC - Developers

Passive Targeting of Solid Tumors 17
For this reason, interest has also been focused on the concept of tumor vasculature as a target rather
than a barrier and is reviewed in this compendium and elsewhere. 49–51
REFERENCES
1. Munn, L. L., Aberrant vascular architecture in tumors and its importance in drug-based therapies,
Drug Discov. Today, 8, 396, 2003.
2. Lyden, D. et al., Impaired recruitment of bone-marrow-derived endothelial and haematopoietic
precursor cells blocks, tumor angiogenesis, and growth, Nat. Med., 7, 1194, 2001.
3. Jain, R. K., Delivery of molecular medicine to solid tumors: Lessons from in vivo imaging of gene
expression and function, J. Control. Release, 74, 7, 2001.
4. Dvorak, H. F. et al., Identification and characterization of the blood vessels of solid tumors that are
leaky to circulating macromolecules, Am. J. Pathol., 133, 95, 1988.
5. Hashizume, H. et al., Openings between defective endothelial cells explain tumor vessel leakiness,
Am. J. Pathol., 156, 1363, 2000.
6. Morikawa, S. et al., Abnormalities in pericytes on blood vessels and endothelial sprouts in tumors,
Am. J. Pathol., 160, 985, 2002.
7. Fukumura, D. et al., Effect of host microenvironment on the microcirculation of human colon adenocarcinoma,
Am. J. Pathol., 151, 679, 1997.
8. Daldrup, H. et al., Correlation of dynamic contrast-enhanced MR imaging with histologic tumor
grade: Comparison of macromolecular and small-molecular contrast media, Am. J. Roentgenol.,
171, 941, 1998.
9. Nathanson, S. D. and Nelson, L., Interstitial fluid pressure in breast cancer, benign breast conditions,
and breast parenchyma, Ann. Surg. Oncol., 1, 333, 1994.
10. Moghimi, S. M., Hunter, A. C., and Murray, J. C., Long-circulating and target-specific nanoparticles:
Theory to practice, Pharmacol. Rev., 53, 283, 2001.
11. Pluen, A. et al., Role of tumor–host interactions in interstitial diffusion of macromolecules: Cranial vs.
subcutaneous tumors, Proc. Natl Acad. Sci. USA, 98, 4628, 2001.
12. Torchilin, V. P., Recent advances with liposomes as pharmaceutical carriers, Nat. Rev. Drug Discov.,
4, 145, 2005.
13. Daemen, T. et al., Liposomal doxorubicin-induced toxicity: Depletion and impairment of phagocytic
activity of liver macrophages, Int. J. Cancer, 61, 716, 1995.
14. Batist, G. et al., Reduced cardiotoxicity and preserved antitumor efficacy of liposome-encapsulated
doxorubicin and cyclophosphamide compared with conventional doxorubicin and cyclophosphamide
in a randomized, multicenter trial of metastatic breast cancer, J. Clin. Oncol., 19, 1444, 2001.
15. Williams, G., Cortazar, P., and Pazdur, R., Developing drugs to decrease the toxicity of
chemotherapy, J. Clin. Oncol., 19, 3439, 2001.
16. Moghimi, S. M., Hunter, A. C., and Murray, J. C., Nanomedicine: Current status and future prospects,
FASEB J., 19, 311, 2005.
17. Gabizon, A., Shmeeda, H., and Barenholz, Y., Pharmacokinetics of pegylated liposomal doxorubicin:
Review of animal and human studies, Clin. Pharmacokinet., 42, 419, 2003.
18. Yuan, F. et al., Microvascular permeability and interstitial penetration of sterically stabilized (stealth)
liposomes in a human tumor xenograft, Cancer Res., 54, 3352, 1994.
19. Bandak, S. et al., Pharmacological studies of cisplatin encapsulated in long-circulating liposomes in
mouse tumor models, Anti-Cancer Drugs, 10, 911, 1999.
20. Huang, S. K. et al., Liposomes and hyperthermia in mice: Increased tumor uptake and therapeutic
efficacy of doxorubicin in sterically stabilized liposomes, Cancer Res., 54, 2186, 1994.
21. Zalipsky, S. et al., New detachable poly(ethylene glycol) conjugates: Cysteine–cleavable lipopolymers
regenerating natural phospholipid, diacylphosphatidylethanolamine, Bioconjug. Chem., 10, 703,
1999.
22. Provoda, C. J. and Lee, K.-D., Bacterial pore-forming hemolysins and their use in the cytosolic
delivery of macromolecules, Adv. Drug Deliv. Rev., 41, 209, 2000.
23. Andresen, T. L., Jensen, S. S., and Jørgensen, K., Advanced strategies in liposomal cancer therapy:
Problems and prospects of active and tumor specific drug release, Prog. Lipid Res., 44, 68, 2005.
q 2006 by Taylor & Francis Group, LLC